Wenjie Zhai

100 Kexue Avenue
Zhengzhou, 450001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

D-peptide-nanodrug conjugates synergize VISTA blockade and innate activation for cancer immunotherapy.

D-peptide-nanodrug conjugates synergize VISTA blockade and innate activation for cancer immunotherapy.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: March 30, 2026

A Bispecific Peptide-Drug Conjugate Targeting LAG-3 and PD-L1 Harnesses Antitumor Immunity of Macrophages and T Cells.

A Bispecific Peptide-Drug Conjugate Targeting LAG-3 and PD-L1 Harnesses Antitumor Immunity of Macrophages and T Cells.

Journal: Journal of medicinal chemistry

Published: March 20, 2026

A novel peptide blocking CD93/IGFBP7 interaction normalizes tumor vessels and synergizes with radiotherapy for cancer immunotherapy.

A novel peptide blocking CD93/IGFBP7 interaction normalizes tumor vessels and synergizes with radiotherapy for cancer immunotherapy.

Journal: Pharmacological research

Published: November 06, 2025

A novel peptide targeting CCR7 inhibits tumor cell lymph node metastasis.

A novel peptide targeting CCR7 inhibits tumor cell lymph node metastasis.

Journal: Cancer immunology, immunotherapy : CII

Published: August 27, 2024

Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy.

Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy.

Journal: BMC biology

Published: May 08, 2024

Identification of a novel DEC-205 binding peptide to develop dendritic cell-targeting nanovaccine for cancer immunotherapy.

Identification of a novel DEC-205 binding peptide to develop dendritic cell-targeting nanovaccine for cancer immunotherapy.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: April 22, 2024

Dual targeting of TIGIT and PD-1 with a novel small molecule for cancer immunotherapy.

Dual targeting of TIGIT and PD-1 with a novel small molecule for cancer immunotherapy.

Journal: Biochemical pharmacology

Published: January 21, 2024

Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy.

Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy.

Journal: Acta pharmaceutica Sinica. B

Published: September 24, 2023

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.

Journal: Cell communication and signaling : CCS

Published: August 21, 2023

Hemin blocks TIGIT/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapy.

Hemin blocks TIGIT/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapy.

Journal: Science China. Life sciences

Published: August 13, 2023

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: May 31, 2023

Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy.

Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy.

Journal: Acta pharmaceutica Sinica. B

Published: March 31, 2023

Showing 1-12 of 37

Last Updated: 09/26/2026